These results may reflect intrinsic characteristics of the disease, given that the majority of RS enrolled patients was pretreated (for CLL and/or RS), and herein potentially exposed to iBTK and prone to acquire resistances to this targeted therapy or even develop gain of function mutations in downstream signaling mediators. The gene discussed is IBTK; the disease is B-cell chronic lymphocytic leukemia.